Fig. 3: Vaccine efficacy using a non-human primate challenge model. | Nature Communications

Fig. 3: Vaccine efficacy using a non-human primate challenge model.

From: saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern

Fig. 3

Adult cynomolgus macaques (n = 5 per group) were injected intramuscularly twice with 50 µg of saRNA-LNP expressing SARS-CoV-2 Spike RBD with HA TM at 0 and 4 weeks. The immunized monkeys were challenged with Wuhan-Hu-1 SARS-CoV-2 via the combination intranasal/intratracheal (IN/IT) route on Day 56. a Antibody titers of sera (Day 54) from the immunized monkeys were evaluated by ELISA against SARS-CoV-2 variant Spike RBD proteins. Plots represent individual endpoint titers with medians. Mann–Whitney U-test was used to determine significance. Experiment was performed two times independently. b Infectious virus titers of BAL (left panel), nasal swab (center panel) and oropharyngeal swab (right panel) samples collected at days 2 and 4 post challenge were analyzed by TCID50 assay.

Back to article page